XOMA Royalty Corporation /
Generation Bio
XOMA Royalty completes Generation Bio acquisition




Source for the buyer and target: XOMA Royalty Corp
For the buyer and target.
“As previously disclosed, XOMA Royalty Corporation (“ XOMA Royalty ”) entered into an Agreement and Plan of Merger, dated December 15, 2025 (the “ Merger Agreement ”), with Generation Bio Co., a Delaware corporation (the “ Company ” or “ Generation Bio ”), and XRA 7 Corp., a Delaware corporation and a wholly owned subsidiary of XOMA Royalty (“ Merger Sub ”).”
Published 27 Apr 2026
Open the sourceWhat happened
XOMA Royalty has completed its acquisition of Generation Bio, carried out through a tender offer followed by a merger in which Generation Bio became a wholly owned subsidiary. Holders received a cash amount per share plus one contingent value right for each share. [01]
XOMA Royalty acquired Generation Bio's remaining cash, certain tax deductions and legacy lipid nanoparticle assets, and it does not plan to continue preclinical development of those assets. [01]
The source
Everything on this page comes from the source below, quoted word for word.
XOMA Royalty completes Generation Bio acquisition
This document is the source for the companies, stage and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly